Biocon said that the USFDA concluded a pre-approval inspection of its insulin drug substance manufacturing facility triggered by a New Drug Application submitted by our insulin AP/customer. The inspection at the Bengaluru facility took place between 25 February 2019 to 5 March 2019, resulting in ...read more
Biocon announced that USFDA concluded a pre-approval inspection of Biocon's insulin drug substance manufacturing facility triggered by a New Drug Application submitted by the c...read more
